{"id":"W4401877498","doi":"10.1016/s2152-2650(24)00991-1","title":"DREAMM-7 Update: Subgroup Analyses From a Phase 3 Trial of Belantamab Mafodotin (Belamaf) + Bortezomib and Dexamethasone (BVd) vs Daratumumab, Bortezomib, and Dexamethasone (DVd) in Relapsed/Refractory Multiple Myeloma (RRMM)","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Medicine; Daratumumab; Dexamethasone; Bortezomib; Oncology; Internal medicine; Multiple myeloma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008886685,0.002920711,0.007345875,0.001026352,0.0004315085,0.002092297,0.001793416,0.00130612,0.005592184],"category_scores_gemma":[0.01035647,0.0009311129,0.01887321,0.001214098,0.0004694888,0.001325236,0.001589977,0.003626445,0.0008510031],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001532063,"about_ca_system_score_gemma":0.001668778,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001918714,"about_ca_topic_score_gemma":0.009800298,"domain_scores_codex":[0.9953665,0.002761726,0.0006107012,0.0005112936,0.000484253,0.0002655875],"domain_scores_gemma":[0.9954997,0.002173461,0.001066004,0.0006073628,0.0003106307,0.0003427505],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5293308,0.0006352796,0.01741779,0.01488791,0.3271295,0.0002455751,0.0002266704,0.002352767,0.003143553,0.0005190544,0.02341079,0.08070032],"study_design_scores_gemma":[0.4866412,0.01025001,0.06045521,0.001551507,0.4081323,0.0004213764,0.0002637023,0.001661737,0.001173888,0.002918623,0.0262952,0.0002351848],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.6045073,0.2815787,0.009065266,0.00897957,0.005023736,0.007303455,0.07321842,0.0009506244,0.009372842],"genre_scores_gemma":[0.8588159,0.04369423,0.0107509,0.00810241,0.002957034,0.009977821,0.05829847,0.0005883977,0.006814849],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008886685,"threshold_uncertainty_score":0.04699785,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07079501631935992,"score_gpt":0.4067195395328916,"score_spread":0.3359245232135317,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}